Clover Biopharmaceuticals Ltd. (2197) AI Stock Analysis

• Market Cap: HK$2.67B
• Dividend Yield: N/A
• Average Volume (3M): 29.82M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.63
• Revenue Growth: 79.98%
• EPS Growth: -3.40%
• Country: HK
• Employees: 300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 1,297,394,200
• 10 Day Avg. Volume: 32,349,599
• 30 Day Avg. Volume: 29,824,166
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.17
• Price to Sales (P/S): 7.39
• P/FCF Ratio: -0.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: HK$2.00 ▼(-9.09% Downside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by significant losses and negative cash flows. While technical analysis provides some positive signals, the negative valuation metrics due to lack of profitability weigh heavily on the score.

Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

How the Company Makes Money

Clover Biopharmaceuticals Ltd. generates revenue primarily through the development and commercialization of its vaccine and therapeutic candidates. The company earns income by licensing its proprietary technology and intellectual property to other pharmaceutical companies, collaborating on co-development projects, and through potential sales of its developed products upon regulatory approval. Strategic partnerships and collaborations with global health organizations and pharmaceutical companies also contribute to its revenue streams. Additionally, government grants and funding for research and development projects in the public health domain can be significant sources of financial support for the company.

Clover Biopharmaceuticals Ltd. Financial Statement Overview

Summary

Clover Biopharmaceuticals faces significant financial challenges, including persistent losses, negative equity, and negative cash flows. High financial leverage and an inability to generate positive cash flow from operations highlight the company's precarious financial position, which could affect its future operations and growth prospects.

Income Statement

Clover Biopharmaceuticals has consistently reported negative net income, with significant losses in gross profit and EBIT. The revenue growth has been negligible, indicating challenges in generating sales. The negative margins reflect difficulty in controlling costs relative to revenue.

Balance Sheet

The company's balance sheet is highly leveraged, with negative stockholders' equity indicating insolvency risks. The debt-to-equity ratio is not meaningful due to negative equity. Asset base is shrinking, and the negative equity ratio suggests financial instability.

Cash Flow

Operating cash flows have been negative, showing challenges in generating cash from operations. The cash position has decreased over time, and free cash flow is consistently negative, which may hinder future growth and investment capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	51.77M	38.42M	39.26M	0.00	0.00	0.00
Gross Profit	-659.39M	-672.94M	24.24M	-475.64M	-66.27M	0.00
EBITDA	-881.50M	-916.54M	-45.07M	-2.37B	-2.23B	-335.04M
Net Income	-909.58M	-903.43M	-138.54M	-2.45B	-6.02B	-915.87M
Balance Sheet
Total Assets	594.21M	812.74M	2.10B	4.69B	5.35B	1.19B
Cash, Cash Equivalents and Short-Term Investments	395.74M	427.53M	766.26M	1.64B	2.87B	806.51M
Total Debt	13.05M	89.64M	334.45M	354.37M	67.92M	22.32M
Total Liabilities	2.30B	2.45B	2.83B	5.36B	4.13B	2.17B
Stockholders Equity	-1.71B	-1.64B	-732.83M	-668.14M	1.22B	-982.74M
Cash Flow
Free Cash Flow	-246.53M	-290.11M	-737.05M	-1.80B	-998.07M	363.13M
Operating Cash Flow	-246.59M	-288.49M	-727.88M	-1.69B	-917.75M	476.93M
Investing Cash Flow	13.95M	3.17M	-6.16M	-37.51M	112.12M	-394.12M
Financing Cash Flow	127.58M	-51.50M	-142.41M	483.14M	3.06B	316.85M

Clover Biopharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2197, the sentiment is Positive. The current price of 2.2 is below the 20-day moving average (MA) of 2.42, above the 50-day MA of 1.86, and above the 200-day MA of 0.69, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.30 is Neutral, neither overbought nor oversold. The STOCH value of 21.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2197.

Clover Biopharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	―	HK$11.43B	17.53	35.80%	―	59.70%	239.97%
2197	―	HK$2.67B	-2.57	―	―	79.98%	-3.40%
2257	―	HK$1.20B	―	―	―	―	83.89%
2179	―	HK$3.40B	―	-129.05%	―	―	-18.99%
6628	―	HK$1.35B	-4.32	-34.18%	―	-57.84%	24.58%
9939	―	HK$921.92M	―	-54.87%	―	―	81.67%

Clover Biopharmaceuticals Ltd. Corporate Events

Clover Biopharmaceuticals Reports Positive Phase I Results for Respiratory Vaccines

Clover Biopharmaceuticals Ltd. announced positive preliminary results from Phase I clinical trials for its combination vaccines targeting RSV, hMPV, and PIV3, as well as for RSV re-vaccination in older adults. The trials demonstrated promising immune responses and safety profiles, with plans to advance to Phase II trials in 2026. These developments could enhance Clover’s positioning in the vaccine market and offer new options for older adults, potentially impacting stakeholders positively.

The most recent analyst rating on (HK:2197) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.

Clover Biopharmaceuticals Reports Interim Financial Results for 2025

Clover Biopharmaceuticals Ltd. announced its interim results for the six months ended June 30, 2025, reporting a decrease in cash and bank balances due to loan repayments and ongoing R&D investments. Despite a reduction in expenses and improved operational efficiency, the company recorded a loss of RMB101.3 million, attributed to the absence of non-recurring income from the previous year.

The most recent analyst rating on (HK:2197) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.

Clover Biopharmaceuticals to Review Interim Financial Results and Dividend Proposal

Clover Biopharmaceuticals Ltd. announced that its board of directors will hold a meeting on August 26, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for an interim dividend, which could impact the company’s financial strategy and shareholder returns.